TY - JOUR
T1 - Immunomodulatory Effects Mediated by Dopamine
AU - Arreola, Rodrigo
AU - Alvarez-Herrera, Samantha
AU - Pérez-Sánchez, Gilberto
AU - Becerril-Villanueva, Enrique
AU - Cruz-Fuentes, Carlos
AU - Flores-Gutierrez, Enrique Octavio
AU - Garcés-Alvarez, María Eugenia
AU - De La Cruz-Aguilera, Dora Luz
AU - Medina-Rivero, Emilio
AU - Hurtado-Alvarado, Gabriela
AU - Quintero-Fabián, Saray
AU - Pavón, Lenin
N1 - Publisher Copyright:
© 2016 Rodrigo Arreola et al.
PY - 2016
Y1 - 2016
N2 - Dopamine (DA), a neurotransmitter in the central nervous system (CNS), has modulatory functions at the systemic level. The peripheral and central nervous systems have independent dopaminergic system (DAS) that share mechanisms and molecular machinery. In the past century, experimental evidence has accumulated on the proteins knowledge that is involved in the synthesis, reuptake, and transportation of DA in leukocytes and the differential expression of the D1-like (D1R and D5R) and D2-like receptors (D2R, D3R, and D4R). The expression of these components depends on the state of cellular activation and the concentration and time of exposure to DA. Receptors that are expressed in leukocytes are linked to signaling pathways that are mediated by changes in cAMP concentration, which in turn triggers changes in phenotype and cellular function. According to the leukocyte lineage, the effects of DA are associated with such processes as respiratory burst, cytokine and antibody secretion, chemotaxis, apoptosis, and cytotoxicity. In clinical conditions such as schizophrenia, Parkinson disease, Tourette syndrome, and multiple sclerosis (MS), there are evident alterations during immune responses in leukocytes, in which changes in DA receptor density have been observed. Several groups have proposed that these findings are useful in establishing clinical status and clinical markers.
AB - Dopamine (DA), a neurotransmitter in the central nervous system (CNS), has modulatory functions at the systemic level. The peripheral and central nervous systems have independent dopaminergic system (DAS) that share mechanisms and molecular machinery. In the past century, experimental evidence has accumulated on the proteins knowledge that is involved in the synthesis, reuptake, and transportation of DA in leukocytes and the differential expression of the D1-like (D1R and D5R) and D2-like receptors (D2R, D3R, and D4R). The expression of these components depends on the state of cellular activation and the concentration and time of exposure to DA. Receptors that are expressed in leukocytes are linked to signaling pathways that are mediated by changes in cAMP concentration, which in turn triggers changes in phenotype and cellular function. According to the leukocyte lineage, the effects of DA are associated with such processes as respiratory burst, cytokine and antibody secretion, chemotaxis, apoptosis, and cytotoxicity. In clinical conditions such as schizophrenia, Parkinson disease, Tourette syndrome, and multiple sclerosis (MS), there are evident alterations during immune responses in leukocytes, in which changes in DA receptor density have been observed. Several groups have proposed that these findings are useful in establishing clinical status and clinical markers.
UR - http://www.scopus.com/inward/record.url?scp=84992436563&partnerID=8YFLogxK
U2 - 10.1155/2016/3160486
DO - 10.1155/2016/3160486
M3 - Artículo de revisión
SN - 2314-8861
VL - 2016
JO - Journal of Immunology Research
JF - Journal of Immunology Research
M1 - 3160486
ER -